Hereditary Transthyretin-mediated Amyloidosis
📧 Sign up to get email alerts when something new happens for Hereditary Transthyretin-mediated Amyloidosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-03-25EMA Authorised: Onpattro (patisiran sodium) — Alnylam Netherlands B.V.
The European Medicines Agency authorised Onpattro (patisiran) for familial hereditary transthyretin-mediated amyloidosis with orphan designa…
-
FDA approval · 2025-03-20FDA Approved: AMVUTTRA — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
FDA approved a supplemental application for AMVUTTRA (vutrisiran) submitted by Alnylam Pharmaceuticals, expanding the approved labeling for …
-
FDA approval · 2021-05-06FDA Approved: ONPATTRO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
FDA approved a supplemental application for ONPATTRO (patisiran) by Alnylam Pharmaceuticals.